Chan Lilian, Moster Marlene R, Bicket Amanda K, Sheybani Arsham, Sarkisian Steven R, Samuelson Thomas W, Ahmed Iqbal Ike K, Miller-Ellis Eydie, Smith Oluwatosin U, Cui Qi N
Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, 51 North 39th St., Philadelphia, PA, 19104, USA.
Wills Eye Hospital, 840 Walnut St, Philadelphia, PA, 19107, USA.
Ophthalmol Ther. 2023 Oct;12(5):2381-2395. doi: 10.1007/s40123-023-00780-3. Epub 2023 Aug 9.
Glaucoma remains a leading cause of blindness globally. Minimally invasive treatment techniques are rapidly expanding the availability of therapeutic options for glaucoma. These include devices aimed at enhancing outflow through the subconjunctival space, Schlemm's canal, and suprachoroidal space, sustained-release drug delivery devices, and extraocular devices aiming to reduce glaucomatous progression through other novel means. In this review, we provide an overview of several novel devices either newly available or in development for the medical and surgical management of glaucoma. Further studies are required to determine the long-term efficacy of these devices and how they will integrate into the current landscape of glaucoma management.
青光眼仍是全球失明的主要原因。微创治疗技术正在迅速扩大青光眼治疗选择的范围。这些技术包括旨在通过结膜下间隙、施莱姆管和脉络膜上腔增强房水流出的装置、缓释药物递送装置,以及旨在通过其他新方法减少青光眼进展的眼外装置。在本综述中,我们概述了几种用于青光眼药物和手术治疗的新装置,这些装置要么已新上市,要么仍在研发中。需要进一步研究来确定这些装置的长期疗效,以及它们将如何融入当前的青光眼治疗格局。